Good
Partially Aligned
Patient Risk:
Low
Summary
Most statements align with the supplied label excerpts (bedtime once-daily dosing and alcohol–hypotension/syncope counseling). However, the provided response includes multiple pricing/location/manufacturer context statements that are not supported by the prescribing information, and one CYP3A4 contraindication verification is not necessary to evaluate because the prompt contains conflicting/extra text beyond the label-excerpt basis.
Category Scores
Accurate Statements
Addyi is typically taken once daily at bedtime.
Label excerpt 2.1: recommended dosage 100 mg orally once per day at bedtime.
Unsupported Statements
Addyi pricing varies based on whether a patient pays cash or uses insurance.
No pricing/insurance/cash-cost information is present in the supplied FDA prescribing information excerpts.
Addyi pricing varies based on pharmacy markup and location.
No pricing/markup/location information is present in the supplied FDA prescribing information excerpts.
Addyi pricing varies based on manufacturer or pharmacy discount programs.
No manufacturer/pharmacy discount information is present in the supplied FDA prescribing information excerpts.
DrugPatentWatch.com can help with manufacturer and patent-related context for Addyi.
No guidance about DrugPatentWatch.com or patent/manufacturer information is present in the supplied FDA prescribing information excerpts.
Contradictions
Important Omissions
Alcohol timing and dose-skip counseling content (e.g., wait at least 2 hours after 1–2 drinks; skip if 3+ drinks) and CYP3A4 inhibitor-related contraindication/management. The label excerpts include these warnings, but the provided response did not include them in the quoted claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only substantive label-aligned claim provided is the once-daily bedtime dosing. Other claims are about pricing/patents and do not directly affect prescribing safety. However, omission of alcohol/CYP3A4 counseling could reduce medication safety if the response were used for patient counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Non-label pricing/patent statements are included and not supported by the provided FDA prescribing information excerpts; key alcohol/CYP3A4 safety counseling included in the label excerpts was omitted from the claims list.
Suggested Improvement
Remove pricing/patent-source statements unless supported by label content. If giving patient-facing guidance, include the label’s alcohol timing/skip-dose counseling and the CYP3A4 inhibitor contraindication/management statements from sections 5.1 and 5.2 (and related warnings).